658 related articles for article (PubMed ID: 25116671)
1. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
3. Fatal Cryptococcus gattii genotype AFLP6/VGII infection in a HIV-negative patient: case report and a literature review.
Favalessa OC; Lázera Mdos S; Wanke B; Trilles L; Takahara DT; Tadano T; Dias LB; Vieira AC; Novack GV; Hahn RC
Mycoses; 2014 Oct; 57(10):639-43. PubMed ID: 24980291
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
[TBL] [Abstract][Full Text] [Related]
6. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
8. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
Herkert PF; Hagen F; de Oliveira Salvador GL; Gomes RR; Ferreira MS; Vicente VA; Muro MD; Pinheiro RL; Meis JF; Queiroz-Telles F
Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1803-1810. PubMed ID: 27477855
[TBL] [Abstract][Full Text] [Related]
10. Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
Kassi FK; Bellet V; Drakulovski P; Krasteva D; Roger F; Valérie BA; Aboubakar T; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Yavo W; Menan HIE; Bertout S
J Med Microbiol; 2018 Jan; 67(1):87-96. PubMed ID: 29214970
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia.
Tomazin R; Matos T; Meis JF; Hagen F
Mycopathologia; 2018 Apr; 183(2):371-380. PubMed ID: 29064061
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology and antifungal susceptibility profiles of clinical
Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
[No Abstract] [Full Text] [Related]
13. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
[TBL] [Abstract][Full Text] [Related]
14. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
15. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
16. First molecular typing of cryptococcemia-causing cryptococcus in central-west Brazil.
Tsujisaki RA; Paniago AM; Lima Júnior MS; Alencar Dde S; Spositto FL; Nunes Mde O; Trilles L; Chang MR
Mycopathologia; 2013 Oct; 176(3-4):267-72. PubMed ID: 23846587
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
18. Primary endemic Cryptococcosis gattii by molecular type VGII in the state of Pará, Brazil.
Santos WR; Meyer W; Wanke B; Costa SP; Trilles L; Nascimento JL; Medeiros R; Morales BP; Bezerra Cde C; Macêdo RC; Ferreira SO; Barbosa GG; Perez MA; Nishikawa MM; Lazéra Mdos S
Mem Inst Oswaldo Cruz; 2008 Dec; 103(8):813-8. PubMed ID: 19148422
[TBL] [Abstract][Full Text] [Related]
19. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
Trilles L; Meyer W; Wanke B; Guarro J; Lazéra M
Med Mycol; 2012 Apr; 50(3):328-32. PubMed ID: 21859388
[TBL] [Abstract][Full Text] [Related]
20. Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.
Singer LM; Meyer W; Firacative C; Thompson GR; Samitz E; Sykes JE
J Clin Microbiol; 2014 Jun; 52(6):2061-70. PubMed ID: 24696030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
